NCT00094146View on ClinicalTrials.gov

Sandostatin LAR® Depot in Patients With Primary Insulin Hypersecretion (PIH) and at Least Moderate Obesity

PHASE2CompletedINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

January 31, 2002

Study Completion Date

December 31, 2002

Conditions
Primary Insulin HypersecretionObesity
Interventions
DRUG

Sandostatin LAR Depot

Trial Locations (3)

38103

University of Tennessee, Memphis

537052

University of Wisconsin Beers-Murphy Clinical Nutrition Clinic, Madison

Unknown

New Orleans Center for Clinical Research, New Orleans

Sponsors

Lead Sponsor

Novartis
All Listed Sponsors
lead

Novartis

INDUSTRY

NCT00094146 - Sandostatin LAR® Depot in Patients With Primary Insulin Hypersecretion (PIH) and at Least Moderate Obesity | Biotech Hunter | Biotech Hunter